Institution
University of Rouen
Education•Rouen, France•
About: University of Rouen is a education organization based out in Rouen, France. It is known for research contribution in the topics: Population & Receptor. The organization has 7299 authors who have published 13209 publications receiving 313477 citations.
Topics: Population, Receptor, Laser, Atom probe, Membrane
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Although mortality was similar in both arms, the rate of stoma reversal was significantly higher in the PA arm, providing additional evidence in favor of PA with diverting ileostomy over HP in patients with diverticular peritonitis.
Abstract: Background About 25% of patients with acute diverticulitis require emergency intervention. Currently, most patients with diverticular peritonitis undergo a Hartmann's procedure. Our objective was to assess whether primary anastomosis (PA) with a diverting stoma results in lower mortality rates than Hartmann's procedure (HP) in patients with diverticular peritonitis. Study Design We conducted a multicenter randomized controlled trial conducted between June 2008 and May 2012: the DIVERTI (Primary vs Secondary Anastomosis for Hinchey Stage III-IV Diverticulitis) trial. Follow-up duration was up to 18 months. A random sample of 102 eligible participants with purulent or fecal diverticular peritonitis from tertiary care referral centers and associated centers in France were equally randomized to either a PA arm or to an HP arm. Data were analyzed on an intention-to-treat basis. The primary end point was mortality rate at 18 months. Secondary outcomes were postoperative complications, operative time, length of hospital stay, rate of definitive stoma, and morbidity. Results All 102 patients enrolled were comparable for age (p = 0.4453), sex (p = 0.2347), Hinchey stage III vs IV (p = 0.2347), and Mannheim Peritonitis Index (p = 0.0606). Overall mortality did not differ significantly between HP (7.7%) and PA (4%) (p = 0.4233). Morbidity for both resection and stoma reversal operations were comparable (39% in the HP arm vs 44% in the PA arm; p = 0.4233). At 18 months, 96% of PA patients and 65% of HP patients had a stoma reversal (p = 0.0001). Conclusions Although mortality was similar in both arms, the rate of stoma reversal was significantly higher in the PA arm. This trial provides additional evidence in favor of PA with diverting ileostomy over HP in patients with diverticular peritonitis. ClinicalTrials.gov Identifier: NCT 00692393.
140 citations
••
TL;DR: It is illustrated that plant-typical N- and O-glycosylation progressively emerge as additional advantages for using this promising expression system.
140 citations
••
TL;DR: The present study shows that removal of this extension and head-tail cyclization of the resulting propeptide are the only post-translational modifications involved in the maturation of MccJ25, that appears as the first cyclic microcin.
Abstract: Microcin J25 (MccJ25) is the single representative of the immunity group J of the microcin group of peptide antibiotics produced by Enterobacteriaceae. It induces bacterial filamentation in susceptible cells in a non-SOS-dependent pathway [R. A. Salomon and R. Farias (1992) J. Bacteriol.174, 7428–7435]. MccJ25 was purified to homogeneity from the growth medium of a microcin-overproducing Escherichia coli strain by reverse-phase HPLC. Based on amino acid composition and absolute configuration determination, liquid secondary ion and electrospray mass spectrometry, extensive two-dimensional NMR, enzymatic and chemical degradations studies, the structure of MccJ25 was elucidated as a 21-residue peptide, cyclo(-Val1-Gly-Ile-Gly-Thr-Pro-Ile-Ser-Phe-Tyr-Gly-Gly-Gly-Ala-Gly-His-Val-Pro-Glu-Tyr-Phe21-). Although MccJ25 showed high resistance to most of endoproteases, linearization by thermolysin occurred from cleavage at the Phe21-Val1 bond and led to a single peptide, MccJ25-L. While MccJ25 exhibited remarkable antibiotic activity towards Salmonella newport and several E. coli strains (minimal inhibitory concentrations ranging between 0.01 and 0.2 µg·mL–1), the thermolysin-linearized microcin showed a dramatic decrease of the activity, indicating that the cyclic structure is essential for the MccJ25 biological properties. As MccJ25 is ribosomally synthesized as a larger peptide precursor endowed with an N-terminal extremity, the present study shows that removal of this extension and head–tail cyclization of the resulting propeptide are the only post-translational modifications involved in the maturation of MccJ25, that appears as the first cyclic microcin.
140 citations
••
TL;DR: In this article, the influence of epitaxial strain on the multiferroic phase transitions of BiFeO3 films was investigated and it was shown that strain can drive both transitions close together to yield increased magnetoelectric responses.
Abstract: We report the influence of epitaxial strain on the multiferroic phase transitions of BiFeO3 films. Using advanced characterization techniques and calculations we show that while the magnetic Ne'el temperature hardly varies, the ferroelectric Curie temperature TC decreases dramatically with strain. This is in contrast with the behavior of standard ferroelectrics where strain enhances the polar cation shifts and thus TC. We argue that this is caused by an interplay of polar and oxygen tilting instabilities and that strain can drive both transitions close together to yield increased magnetoelectric responses.
140 citations
••
TL;DR: Apremilast demonstrated an acceptable safety profile and was generally well tolerated for ≥156 weeks and no serious opportunistic infections, reactivation of tuberculosis, or clinically meaningful effects on laboratory measurements were reported.
Abstract: Background Randomized, controlled trials demonstrated efficacy and safety of apremilast for moderate-to-severe plaque psoriasis and psoriatic arthritis. Objective Assess long-term safety of oral apremilast in psoriasis patients. Methods Safety findings are reported for 0 to ≥156 weeks from the Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) 1 and 2. Results The 0 to ≥156–week apremilast-exposure period included 1184 patients treated twice daily with apremilast 30 mg (1902.2 patient-years). During 0 to ≤52 weeks, the adverse events (AEs) that occurred in ≥5% of patients included diarrhea, nausea, upper respiratory tract infection, nasopharyngitis, tension headache, and headache. From 0 to ≥156 weeks, no new AEs (affecting ≥5% of the population) were reported. AEs, serious AEs, and study drug discontinuations caused by AEs did not increase with long-term exposure. During the 0 to ≥156–week period, the rates of major cardiac events (exposure-adjusted incidence rate [EAIR] 0.5/100 patient-years), malignancies (EAIR 1.2/100 patient-years), depression (EAIR 1.8/100 patient-years), or suicide attempts (EAIR 0.1/100 patient-years) did not increase in comparison with the rates found during the 0 to ≤52–week period. No serious opportunistic infections, reactivation of tuberculosis, or clinically meaningful effects on laboratory measurements were reported. Limitations This study had a high dropout rate (21% of patients ongoing >156 weeks); most were unrelated to safety concerns. Conclusions Apremilast demonstrated an acceptable safety profile and was generally well tolerated for ≥156 weeks.
139 citations
Authors
Showing all 7360 results
Name | H-index | Papers | Citations |
---|---|---|---|
Yves Agid | 141 | 669 | 74441 |
Alexis Brice | 135 | 870 | 83466 |
Mohamed Eddaoudi | 94 | 327 | 64217 |
Hervé Tilly | 86 | 479 | 30321 |
David Cohen | 83 | 635 | 37722 |
Jörg Neugebauer | 81 | 491 | 30909 |
Hubert Vaudry | 80 | 975 | 34350 |
Michel Baudry | 80 | 372 | 23890 |
Richard L. Stevens | 79 | 264 | 19148 |
Claudine Berr | 75 | 297 | 27919 |
Christian P. Robert | 75 | 535 | 36864 |
Thierry Frebourg | 71 | 307 | 22403 |
Georges Pelletier | 69 | 432 | 19018 |
Michel Vert | 69 | 333 | 17899 |
Jean-Charles Schwartz | 69 | 252 | 15917 |